59
Forensic Drug Testing Part 2: GC/MS Confirmation Roger L. Bertholf, Ph.D. Associate Professor of Pathology Chief of Clinical Chemistry & Toxicology

Forensic Drug Testing Part 2: GC/MS Confirmation Roger L. Bertholf, Ph.D. Associate Professor of Pathology Chief of Clinical Chemistry & Toxicology Roger

Embed Size (px)

Citation preview

Page 1: Forensic Drug Testing Part 2: GC/MS Confirmation Roger L. Bertholf, Ph.D. Associate Professor of Pathology Chief of Clinical Chemistry & Toxicology Roger

Forensic Drug TestingPart 2: GC/MS Confirmation

Forensic Drug TestingPart 2: GC/MS Confirmation

Roger L. Bertholf, Ph.D.

Associate Professor of Pathology

Chief of Clinical Chemistry & Toxicology

Roger L. Bertholf, Ph.D.

Associate Professor of Pathology

Chief of Clinical Chemistry & Toxicology

Page 2: Forensic Drug Testing Part 2: GC/MS Confirmation Roger L. Bertholf, Ph.D. Associate Professor of Pathology Chief of Clinical Chemistry & Toxicology Roger

Screening vs. ConfirmationScreening vs. Confirmation

• Low cost• Fast• Semi-quantitative• High sensitivity• Low specificity

• Low cost• Fast• Semi-quantitative• High sensitivity• Low specificity

• High cost• Slow• Quantitative• High sensitivity• High specificity

• High cost• Slow• Quantitative• High sensitivity• High specificity

Page 3: Forensic Drug Testing Part 2: GC/MS Confirmation Roger L. Bertholf, Ph.D. Associate Professor of Pathology Chief of Clinical Chemistry & Toxicology Roger

A confirmatory method should . . .A confirmatory method should . . .

• Utilize the most accurate (specific) testing method available

• Have sensitivity equal to or better than the screening method

• Be economically feasible• Be simple enough to standardize across

many laboratories• Produce results that are legally defensible

• Utilize the most accurate (specific) testing method available

• Have sensitivity equal to or better than the screening method

• Be economically feasible• Be simple enough to standardize across

many laboratories• Produce results that are legally defensible

Page 4: Forensic Drug Testing Part 2: GC/MS Confirmation Roger L. Bertholf, Ph.D. Associate Professor of Pathology Chief of Clinical Chemistry & Toxicology Roger

ChromatographyChromatography

• Separation of components based on their. . .– Solubility in mobile and stationary phases

• Terminology:– Gas/liquid– Liquid/liquid– Ion exchange– Partition

• Separation of components based on their. . .– Solubility in mobile and stationary phases

• Terminology:– Gas/liquid– Liquid/liquid– Ion exchange– Partition

Page 5: Forensic Drug Testing Part 2: GC/MS Confirmation Roger L. Bertholf, Ph.D. Associate Professor of Pathology Chief of Clinical Chemistry & Toxicology Roger

Chromatographic separationsChromatographic separations

Stationary Phase

Mobile Phase

Page 6: Forensic Drug Testing Part 2: GC/MS Confirmation Roger L. Bertholf, Ph.D. Associate Professor of Pathology Chief of Clinical Chemistry & Toxicology Roger

Chromatographic separationsChromatographic separations

A B

Soluble in stationary phaseLong retention time

Soluble in mobile phaseShort retention time

Page 7: Forensic Drug Testing Part 2: GC/MS Confirmation Roger L. Bertholf, Ph.D. Associate Professor of Pathology Chief of Clinical Chemistry & Toxicology Roger

Chromatographic separationsChromatographic separationsD

etec

tor

sign

al

Time

B

A The resolution of a chromatographicseparation is defined as:

t/mean peak width

Page 8: Forensic Drug Testing Part 2: GC/MS Confirmation Roger L. Bertholf, Ph.D. Associate Professor of Pathology Chief of Clinical Chemistry & Toxicology Roger

Chromatographic resolutionChromatographic resolution

w(A) w(B)

Vr

2

)()()()(

BwAwAVBV

R rrs

Page 9: Forensic Drug Testing Part 2: GC/MS Confirmation Roger L. Bertholf, Ph.D. Associate Professor of Pathology Chief of Clinical Chemistry & Toxicology Roger

Chromatographic resolutionChromatographic resolution

• The resolution, Rs, is a unitless quantity since it is the ratio of two measures of retention (time, volume, or distance).

• In general, in order to satisfactorily separate equal amounts of compounds A and B, the Rs must be greater than 0.8—baseline separation requires an Rs greater than 1.25.

• The resolution, Rs, is a unitless quantity since it is the ratio of two measures of retention (time, volume, or distance).

• In general, in order to satisfactorily separate equal amounts of compounds A and B, the Rs must be greater than 0.8—baseline separation requires an Rs greater than 1.25.

Page 10: Forensic Drug Testing Part 2: GC/MS Confirmation Roger L. Bertholf, Ph.D. Associate Professor of Pathology Chief of Clinical Chemistry & Toxicology Roger

Column efficiencyColumn efficiency

4

2

)(

)(

A

AVN r

N

LHETP

Page 11: Forensic Drug Testing Part 2: GC/MS Confirmation Roger L. Bertholf, Ph.D. Associate Professor of Pathology Chief of Clinical Chemistry & Toxicology Roger

Peak broadeningPeak broadening

Time

Page 12: Forensic Drug Testing Part 2: GC/MS Confirmation Roger L. Bertholf, Ph.D. Associate Professor of Pathology Chief of Clinical Chemistry & Toxicology Roger

The van Deemter equationThe van Deemter equation

= Flow rateA = Eddy diffusion componentB = Longitudinal diffusion componentC = Mass transfer term

= Flow rateA = Eddy diffusion componentB = Longitudinal diffusion componentC = Mass transfer term

CB

AHETP

Page 13: Forensic Drug Testing Part 2: GC/MS Confirmation Roger L. Bertholf, Ph.D. Associate Professor of Pathology Chief of Clinical Chemistry & Toxicology Roger

The van Deemter equationThe van Deemter equation

CB

AHETP

If we. . . A B C

Increase the temperature + + -

Increase the flow rate +/- - +

Decrease specimen volume +/- +/- -

Page 14: Forensic Drug Testing Part 2: GC/MS Confirmation Roger L. Bertholf, Ph.D. Associate Professor of Pathology Chief of Clinical Chemistry & Toxicology Roger

Packed vs. capillary GC columnPacked vs. capillary GC column1-2 m

15-60 m

Page 15: Forensic Drug Testing Part 2: GC/MS Confirmation Roger L. Bertholf, Ph.D. Associate Professor of Pathology Chief of Clinical Chemistry & Toxicology Roger

The van Deemter equationThe van Deemter equation

= Flow rateA = Eddy diffusion componentB = Longitudinal diffusion componentC = Mass transfer term

= Flow rateA = Eddy diffusion componentB = Longitudinal diffusion componentC = Mass transfer term

CB

AHETP

Page 16: Forensic Drug Testing Part 2: GC/MS Confirmation Roger L. Bertholf, Ph.D. Associate Professor of Pathology Chief of Clinical Chemistry & Toxicology Roger

Gas chromatography stationary phases

Gas chromatography stationary phases

Stationary phase Polarity

100% dimethyl-polysiloxane Non-polar

50% diphenyl-50% dimethyl-polysiloxane Intermediate

Polyethylene glycol (Carbowax®) Polar

Page 17: Forensic Drug Testing Part 2: GC/MS Confirmation Roger L. Bertholf, Ph.D. Associate Professor of Pathology Chief of Clinical Chemistry & Toxicology Roger

GC injection techniquesGC injection techniques

• Split injections

• Splitless (Gröb) injections

• On-column injections

• Split injections

• Splitless (Gröb) injections

• On-column injections

Page 18: Forensic Drug Testing Part 2: GC/MS Confirmation Roger L. Bertholf, Ph.D. Associate Professor of Pathology Chief of Clinical Chemistry & Toxicology Roger

Split injectionsSplit injections

Purge/carrier gas inlet

Purge gas exit (90 – 99%)Split valve

Septum

To GC column (1 – 10%)

Injectorbody

Page 19: Forensic Drug Testing Part 2: GC/MS Confirmation Roger L. Bertholf, Ph.D. Associate Professor of Pathology Chief of Clinical Chemistry & Toxicology Roger

Splitless injectionsSplitless injections

Purge/carrier gas inlet

Purge gas exit

Split valve (shut)

Septum

To GC column (>95%)

Injectorbody

Page 20: Forensic Drug Testing Part 2: GC/MS Confirmation Roger L. Bertholf, Ph.D. Associate Professor of Pathology Chief of Clinical Chemistry & Toxicology Roger

Other inlet systemsOther inlet systems

• Solid probe

• Liquid chromatograph

• Mass spectrometer?

• Solid probe

• Liquid chromatograph

• Mass spectrometer?

Page 21: Forensic Drug Testing Part 2: GC/MS Confirmation Roger L. Bertholf, Ph.D. Associate Professor of Pathology Chief of Clinical Chemistry & Toxicology Roger

Electron impact ionizationElectron impact ionization

e-

e-

++ +

(+)

From GC

To MS

Filament

CollectorIon volume(or source)

Focusinglens

(-)

Power supply

Page 22: Forensic Drug Testing Part 2: GC/MS Confirmation Roger L. Bertholf, Ph.D. Associate Professor of Pathology Chief of Clinical Chemistry & Toxicology Roger

Other ionization methodsOther ionization methods

• Chemical ionization

• Thermospray

• Electrospray

• Fast atom bombardment (FAB)

• Matrix-assisted Laser Desorption (MALDI)

• Chemical ionization

• Thermospray

• Electrospray

• Fast atom bombardment (FAB)

• Matrix-assisted Laser Desorption (MALDI)

Page 23: Forensic Drug Testing Part 2: GC/MS Confirmation Roger L. Bertholf, Ph.D. Associate Professor of Pathology Chief of Clinical Chemistry & Toxicology Roger

The “Right Hand Rule”The “Right Hand Rule”

Direction of current

Direction ofmagneticfield

Page 24: Forensic Drug Testing Part 2: GC/MS Confirmation Roger L. Bertholf, Ph.D. Associate Professor of Pathology Chief of Clinical Chemistry & Toxicology Roger

Magnetic sector mass spectrometerMagnetic sector mass spectrometer

To detector

+

From ion source

Page 25: Forensic Drug Testing Part 2: GC/MS Confirmation Roger L. Bertholf, Ph.D. Associate Professor of Pathology Chief of Clinical Chemistry & Toxicology Roger

Quadrupole mass spectrometerQuadrupole mass spectrometer

+

From ion source To detector

Page 26: Forensic Drug Testing Part 2: GC/MS Confirmation Roger L. Bertholf, Ph.D. Associate Professor of Pathology Chief of Clinical Chemistry & Toxicology Roger

Other types of mass filtersOther types of mass filters

• Ion trap

• Ion cyclotron

• Time of flight

• Ion trap

• Ion cyclotron

• Time of flight

Page 27: Forensic Drug Testing Part 2: GC/MS Confirmation Roger L. Bertholf, Ph.D. Associate Professor of Pathology Chief of Clinical Chemistry & Toxicology Roger

Electron multiplierElectron multiplier

e-

104 e-+

From mass filter

Positive dynode

Negative dynode

Ammeter

Page 28: Forensic Drug Testing Part 2: GC/MS Confirmation Roger L. Bertholf, Ph.D. Associate Professor of Pathology Chief of Clinical Chemistry & Toxicology Roger

Mass spectrumMass spectrum

0

10

20

30

40

50

60

70

80

90

100

40 50 60 70 80 90 100 110 120 130 140 150 160 170 180 190 200 210 220 230 240 250 260 270 280

Page 29: Forensic Drug Testing Part 2: GC/MS Confirmation Roger L. Bertholf, Ph.D. Associate Professor of Pathology Chief of Clinical Chemistry & Toxicology Roger

Single ion monitoring (SIM)Single ion monitoring (SIM)

Time

m/

z

Full scan time = 1.0 sec(0.002 sec/ion)

0.1s

Page 30: Forensic Drug Testing Part 2: GC/MS Confirmation Roger L. Bertholf, Ph.D. Associate Professor of Pathology Chief of Clinical Chemistry & Toxicology Roger

CocaineCocaine

N

H3C

O

O

CH3

O

O

C17H21NO4

MW=303.35

Page 31: Forensic Drug Testing Part 2: GC/MS Confirmation Roger L. Bertholf, Ph.D. Associate Professor of Pathology Chief of Clinical Chemistry & Toxicology Roger

303 (M+)

[M-31]+ 272

182 [M-121]+

82 (base peak)

121

Page 32: Forensic Drug Testing Part 2: GC/MS Confirmation Roger L. Bertholf, Ph.D. Associate Professor of Pathology Chief of Clinical Chemistry & Toxicology Roger

Cocaine fragmentation (EI)Cocaine fragmentation (EI)

N

H3C

O

OCH3

O

O

N

H3C

O

OCH3

O

O

N

H3C

O

OCH3

O

O

N

H3C

O

O

CH3

O

O

272 31

82

121182

303

unstable

Page 33: Forensic Drug Testing Part 2: GC/MS Confirmation Roger L. Bertholf, Ph.D. Associate Professor of Pathology Chief of Clinical Chemistry & Toxicology Roger

303 (M+)

[M-31]+ 272

182 [M-121]+

82 (base peak)

121

Page 34: Forensic Drug Testing Part 2: GC/MS Confirmation Roger L. Bertholf, Ph.D. Associate Professor of Pathology Chief of Clinical Chemistry & Toxicology Roger

Amphetamine/MethamphetamineAmphetamine/Methamphetamine

HN

CH3

Methamphetamine

CH3

CH3

Amphetamine

NH2

Page 35: Forensic Drug Testing Part 2: GC/MS Confirmation Roger L. Bertholf, Ph.D. Associate Professor of Pathology Chief of Clinical Chemistry & Toxicology Roger

44

91

Page 36: Forensic Drug Testing Part 2: GC/MS Confirmation Roger L. Bertholf, Ph.D. Associate Professor of Pathology Chief of Clinical Chemistry & Toxicology Roger

Amphetamine fragmentationAmphetamine fragmentation

CH3

NH2CH3

NH2

44

91

+

+

Page 37: Forensic Drug Testing Part 2: GC/MS Confirmation Roger L. Bertholf, Ph.D. Associate Professor of Pathology Chief of Clinical Chemistry & Toxicology Roger

44

91

Page 38: Forensic Drug Testing Part 2: GC/MS Confirmation Roger L. Bertholf, Ph.D. Associate Professor of Pathology Chief of Clinical Chemistry & Toxicology Roger

Methamphetamine fragmentationMethamphetamine fragmentation

HN

CH3

CH3

HN

CH3

CH3+

91

+

58

Page 39: Forensic Drug Testing Part 2: GC/MS Confirmation Roger L. Bertholf, Ph.D. Associate Professor of Pathology Chief of Clinical Chemistry & Toxicology Roger

58

91

Page 40: Forensic Drug Testing Part 2: GC/MS Confirmation Roger L. Bertholf, Ph.D. Associate Professor of Pathology Chief of Clinical Chemistry & Toxicology Roger

TMS derivative of amphetamineTMS derivative of amphetamine

CH3

NH2

BSTFA

CH3

HN

Si(CH3)3

Amphetamine TMS-AmphetamineMW = 207

Page 41: Forensic Drug Testing Part 2: GC/MS Confirmation Roger L. Bertholf, Ph.D. Associate Professor of Pathology Chief of Clinical Chemistry & Toxicology Roger

TMS-amphetamine fragmentationTMS-amphetamine fragmentation

CH3

HN

Si(CH3)3

CH3

HN

Si(CH3)2

CH3

NH

Si(CH3)3

116

91

+

+

192

+

Page 42: Forensic Drug Testing Part 2: GC/MS Confirmation Roger L. Bertholf, Ph.D. Associate Professor of Pathology Chief of Clinical Chemistry & Toxicology Roger

Mass spectra of TMS-amphetamineMass spectra of TMS-amphetamine

Page 43: Forensic Drug Testing Part 2: GC/MS Confirmation Roger L. Bertholf, Ph.D. Associate Professor of Pathology Chief of Clinical Chemistry & Toxicology Roger

TMS-methamphetamine fragmentationTMS-methamphetamine fragmentation

N

CH3

CH3

Si(CH3)3

N

CH3

CH3

Si(CH3)3

N

CH3

CH2

Si(CH3)3

+

91

+

130

206

+

Page 44: Forensic Drug Testing Part 2: GC/MS Confirmation Roger L. Bertholf, Ph.D. Associate Professor of Pathology Chief of Clinical Chemistry & Toxicology Roger

Mass spectra of TMS-methamphetamine

Mass spectra of TMS-methamphetamine

Page 45: Forensic Drug Testing Part 2: GC/MS Confirmation Roger L. Bertholf, Ph.D. Associate Professor of Pathology Chief of Clinical Chemistry & Toxicology Roger

Methamphetamine metabolismMethamphetamine metabolism

CH3

Amphetamine

NH2

HN

H3C H

d-Methamphetamine

HN

H CH3

l-Desoxyephedrine

CH3

~10%

Page 46: Forensic Drug Testing Part 2: GC/MS Confirmation Roger L. Bertholf, Ph.D. Associate Professor of Pathology Chief of Clinical Chemistry & Toxicology Roger

Cocaine HCl and free base formsCocaine HCl and free base forms

N

H3C

O

O

CH3

O

O

NH+

H3C

O

O

CH3

O

O

Cl-

pH<8.6

HCl

Page 47: Forensic Drug Testing Part 2: GC/MS Confirmation Roger L. Bertholf, Ph.D. Associate Professor of Pathology Chief of Clinical Chemistry & Toxicology Roger

Cocaine metabolismCocaine metabolism

N

H3C

O

O

CH3

O

O

N

H3C

O

O

CH3

OH

N

H3C

OH

O

O

O

HN

O

O

CH3

O

O

Ecgonine methyl ester Benzoylecgonine Norcocaine

- C6H5COO

- CH3

- CH3

Page 48: Forensic Drug Testing Part 2: GC/MS Confirmation Roger L. Bertholf, Ph.D. Associate Professor of Pathology Chief of Clinical Chemistry & Toxicology Roger

TMS derivative of benzoylecgonineTMS derivative of benzoylecgonine

N

H3C

OH

O

O

O

BSTFA

N

H3C

O

O

O

O

Si(CH3)3

BenzyolecgonineMW = 289

TMS-BenzyolecgonineMW = 361

Page 49: Forensic Drug Testing Part 2: GC/MS Confirmation Roger L. Bertholf, Ph.D. Associate Professor of Pathology Chief of Clinical Chemistry & Toxicology Roger

TMS-benzoylecgonine fragmentationTMS-benzoylecgonine fragmentation

N

H3C

O

OSi(CH3)3

O

O

N

H3C

O

OSi(CH3)3

N

H3C

O

O

N

H3CO

O

OO

Si(CH3)2

346

82

122240

361

+

+

Page 50: Forensic Drug Testing Part 2: GC/MS Confirmation Roger L. Bertholf, Ph.D. Associate Professor of Pathology Chief of Clinical Chemistry & Toxicology Roger

Mass spectra of TMS-benzoylecgonine

Mass spectra of TMS-benzoylecgonine

Page 51: Forensic Drug Testing Part 2: GC/MS Confirmation Roger L. Bertholf, Ph.D. Associate Professor of Pathology Chief of Clinical Chemistry & Toxicology Roger

OpiatesOpiates

OHO OH

N

H3C

H

OO OH

N

H3C

H

H3C

Morphine Codeine

CH3

Page 52: Forensic Drug Testing Part 2: GC/MS Confirmation Roger L. Bertholf, Ph.D. Associate Professor of Pathology Chief of Clinical Chemistry & Toxicology Roger

GlucuronidationGlucuronidation

OHO OH

N

H3C

H

OH

HO

OH

HH

OHH

OH

COOH

OC6H9O7 C6H9O7

N

H3C

H

Morphine

Hepatic glucuronyl transferase

Morphine diglucuronide

-D-glucuronic acid

Page 53: Forensic Drug Testing Part 2: GC/MS Confirmation Roger L. Bertholf, Ph.D. Associate Professor of Pathology Chief of Clinical Chemistry & Toxicology Roger

Morphine hydrolysisMorphine hydrolysis

OC6H9O7 C6H9O7

N

H3C

H

OHO OH

N

H3C

H

MorphineMorphine diglucuronide

-glucuronidase

Page 54: Forensic Drug Testing Part 2: GC/MS Confirmation Roger L. Bertholf, Ph.D. Associate Professor of Pathology Chief of Clinical Chemistry & Toxicology Roger

TMS derivative of codeineTMS derivative of codeine

OO OH

N

H3C

H

H3C

BSTFA

OO O

N

H3C

H

H3C Si(CH3)3

CodeineMW = 299

TMS-CodeineMW = 371

Page 55: Forensic Drug Testing Part 2: GC/MS Confirmation Roger L. Bertholf, Ph.D. Associate Professor of Pathology Chief of Clinical Chemistry & Toxicology Roger

Mass spectra of TMS-codeineMass spectra of TMS-codeine

Page 56: Forensic Drug Testing Part 2: GC/MS Confirmation Roger L. Bertholf, Ph.D. Associate Professor of Pathology Chief of Clinical Chemistry & Toxicology Roger

Heroin metabolismHeroin metabolism

OO O

N

H3C

H

Heroin

OHO OH

N

H3C

H

Morphine

H3C

O

CH3

O

OHO O

N

H3C

H

6-Monoacetylmorphine CH3

O

- CH3CO

- CH3CO

Page 57: Forensic Drug Testing Part 2: GC/MS Confirmation Roger L. Bertholf, Ph.D. Associate Professor of Pathology Chief of Clinical Chemistry & Toxicology Roger

9-Tetrahydrocannabinol (THC)9-Tetrahydrocannabinol (THC)

O

CH3

OH

H3C

H3CO

COOH

OH

H3C

H3C

Oxidation

9-THC 9-THC-COOH

Page 58: Forensic Drug Testing Part 2: GC/MS Confirmation Roger L. Bertholf, Ph.D. Associate Professor of Pathology Chief of Clinical Chemistry & Toxicology Roger

THC-COOH detectionTHC-COOH detection

THC-COOH glucuronide (15%)

THC-COOH

TMS-THC-COOH

Hydrolysis

BSTFA

Page 59: Forensic Drug Testing Part 2: GC/MS Confirmation Roger L. Bertholf, Ph.D. Associate Professor of Pathology Chief of Clinical Chemistry & Toxicology Roger

Thank You!

Questions?